Effect of genetic variation in STXBP5 and STX2 on von Willebrand factor and bleeding phenotype in type 1 von Willebrand disease patients.

by Janine E van Loon, Yvonne V Sanders, Eva M de Wee, Marieke J H A Kruip, Moniek P M de Maat, Frank W G Leebeek
Published 2012-01-01

Caging the dragon: Research approach to COVID‐19–related thrombosis

by Marieke J. H. A. Kruip, Suzanne C. Cannegieter, Hugo ten Cate, Eric C. M. vanGorp, Nicole P. Juffermans, Frederikus A. Klok, Coen Maas, Anton Vonk‐Noordegraaf, Dutch & COVID Thrombosis Coalition study group
Published 2021-02-01

Effect of antithrombotic stewardship on the efficacy and safety of antithrombotic therapy during and after hospitalization.

by Albert R Dreijer, Marieke J H A Kruip, Jeroen Diepstraten, Suzanne Polinder, Rolf Brouwer, Peter G M Mol, F Nanne Croles, Esther Kragten, Frank W G Leebeek, Patricia M L A van den Bemt
Published 2020-01-01

Congenital platelet disorders and health status–related quality of life

by Maaike W. Blaauwgeers, Marieke J. H. A. Kruip, Erik A. M. Beckers, Michiel Coppens, Jeroen Eikenboom, Karin P. M. vanGalen, Rienk Y. J. Tamminga, Rolf T. Urbanus, Roger E. G. Schutgens, the TiN study group
Published 2020-01-01

von Willebrand Factor is elevated in HIV patients with a history of thrombosis

by Lennert W.J. van den Dries, Rob A. Gruters, Sascha B.C. Hövels – van der Borden, Marieke J.H.A. Kruip, Moniek ede Maat, Eric C.M. van Gorp, Eric C.M. van Gorp, Marchina E. van der Ende
Published 2015-03-01

Heavy menstrual bleeding on direct factor Xa inhibitors: Rationale and design of the MEDEA study

by Eva N. Hamulyák, Hanke M. G. Wiegers, Luuk J. J. Scheres, Barbara A. Hutten, Maria E. deLange, Anne Timmermans, Peter E. Westerweel, Marten R. Nijziel, Marieke J. H. A. Kruip, Marije ten Wolde, Paula F. Ypma, Frederikus A. Klok, Laurens Nieuwenhuizen, Sanne vanWissen, Marcel M. C. Hovens, Laura M. Faber, Pieter W. Kamphuisen, Harry R. Büller, Saskia Middeldorp
Published 2021-01-01